The PFP products protect medicines from contamination. They include a combination of a formulation without chemical preservatives, a pump system that filters or blocks the returning air, and an actuator that prevents bacterial ingress into the dispenser.
MWV says the five-fold mechanical protection system assures germ-free pump dosing to the patient. It includes non-return valves next to the orifice bore and in the metering chamber, and a filter element for contamination-free ventilation of the container, a locked actuator, and a sealed air path during storage.
The PFP T delivers volumes from 0.05mL to 0.14mL. Upside down and tamper-evident features are also available with the product.
‘We are expanding the range of preservative free pumps to meet consumer demand for preservative-free formulations,’ said Chris Hall, vice president and managing director, Medical Plastics Division, MWV Healthcare.
‘This technology does more than protect preservative free medicines from contamination, it is also suitable for use with other topical or dermal products where protecting the formulation and maintaining sterility is important, and necessary.’
MWV Healthcare expands preservative free pumps line
Manufacturing facility awarded certification for PFP spray systems
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
Upcoming event
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
Semaglutide patent cliff: pharma industry braces for impact
With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities
The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258
The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists